Stefanie D Krens
6PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jul 08, 2025
Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability-enhancing strategies.Daan W Huntjens, Olivier J M Béquignon, Stefanie D Krens
|Mar 03, 2022
Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer.Stefanie D Krens, Nielka P van Erp, Stefanie L Groenland
|Dec 02, 2021
Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites.Stefanie D Krens, Sasja F Mulder, Nielka P van Erp
|Sep 08, 2021
Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer.Stefanie D Krens, Wim van Boxtel, Maike J M Uijen
|Jan 11, 2021
The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure.Stefanie D Krens, Floor J E Lubberman, Marthe van Egmond
|Nov 24, 2019
Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.Stefanie D Krens, Eric van der Meulen, Frank G A Jansman
Pageof 1
Frequent Collaborators
1 joint publications
Wim van Boxtel
1 joint publications
Daan W Huntjens
1 joint publications
Olivier J M Béquignon
1 joint publications
Mark Löwenberg
1 joint publications
Martine E D Chamuleau
1 joint publications
Remco J Molenaar
1 joint publications
Marianne A Kuijvenhoven
1 joint publications
Imke H Bartelink
